CAR-T– tag –
-
DelveInsight: 180+ Companies Propel CAR-T Innovation, Forging a New Era in Cell Therapy
DelveInsight USA Overview A new DelveInsight report reveals the significant expansion of the CAR-T cell therapy pipeline, with over 180 companies driving innovation. Projecting substantial market growth by 2036, the report highlights key... -
Allogene Therapeutics’ Anti-B7-H3 Allogeneic CAR γδ T Cell Therapy QH104 Shows Favorable Safety, Disease Stabilization in Leptomeningeal Metastasis Phase 1 Trial
PubMed USA Overview Allogene Therapeutics' anti-B7-H3 allogeneic CAR γδ T cell therapy, QH104, demonstrated a favorable safety profile and promising efficacy in a Phase 1 clinical trial for patients with leptomeningeal metastasis (LM) fr... -
CRISPR Gene Editing Evolves with Cas12a2 to Shred Sick Cell DNA, Expanding Therapeutic Horizons for Cancer and Viral Infections
Top Doctor Magazine USA Overview The CRISPR gene editing landscape is rapidly evolving in 2026, driven by the FDA approval of Cas9-based CASGEVY and the discovery of the novel Cas12a2 protein's ability to 'shred' diseased cell DNA. Unlik... -
iRegene Therapeutics’ NouvNeu001 Secures Dual FDA Expedited Designations: A New Regulatory Milestone for iPSC Therapies
RegMedNet UK Overview iRegene Therapeutics announced its allogeneic iPSC-derived therapy, NouvNeu001, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for Parkinson's disease, following its prior Fast ... -
The In Vivo CAR-T Race Heats Up: Big Pharma Acquisitions and Astellas’ Strategic Collaborations Signal a New Era in Cancer Therapy
Answers（アンサーズ） Japan Overview The global race to develop 'in vivo CAR-T therapy,' which generates CAR-T cells directly within the patient's body, is intensely accelerating as major pharmaceutical companies invest heavily. This inn... -
ProBio and Curocell Achieve BLA Approval for Next-Gen CD19-Targeted CAR-T Therapy, Initiating Commercial Production in South Korea
ProBio CDMO South Korea Overview ProBio CDMO and Curocell have secured Biologics License Application (BLA) approval for anbalcabtagene autoleucel (Anbal-cel; CRC01), their next-generation CD19-targeted CAR-T cell therapy for relapsed or ... -
Aldevron and Minaris Renew Lentiviral Plasmid Agreement, Bolstering Critical Supply for Advanced Cell and Gene Therapies
BioBuzz USA Overview Aldevron and Minaris have renewed their lentiviral plasmid licensing agreement, significantly expanding access to scalable plasmid solutions essential for advanced cell and gene therapy (CGT) developers. This collabo...
